Cargando…

Pembrolizumab combined with axitinib in the treatment of skin metastasis of renal clear cell carcinoma to nasal ala: A case report

BACKGROUND: Renal clear cell carcinoma (RCC) is a malignant tumor of the genitourinary system with a predilection for males. The most common metastatic sites are the lung, liver, lymph nodes, contralateral kidney or adrenal gland, however, skin metastasis has only been seen in 1.0%-3.3% of cases. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Shuai, Xu, Yang-Chun, Zhang, Yuan-Chen, Xia, Jian-Xin, Mou, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10044962/ https://www.ncbi.nlm.nih.gov/pubmed/36998957 http://dx.doi.org/10.12998/wjcc.v11.i9.2104

Ejemplares similares

Comparative Effectiveness of Front-Line Ipilimumab and Nivolumab or Axitinib and Pembrolizumab in Metastatic Clear Cell Renal Cell Carcinoma
por: Zarrabi, Kevin K, et al.
Publicado: (2022)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
por: Gurruchaga Sotés, Ibon, et al.
Publicado: (2021)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020)

Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature
por: Beirat, Amir F., et al.
Publicado: (2023)

Symptomatic methemoglobinemia in a patient with metastatic clear cell renal cell carcinoma treated with pembrolizumab and axitinib combination therapy: a case report
por: Olsen, T. Anders, et al.
Publicado: (2021)

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a)
por: Stellato, Marco, et al.
Publicado: (2023)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
por: Chau, Vincent, et al.
Publicado: (2020)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
por: Katsumata, Yuki, et al.
Publicado: (2021)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
por: Tamada, Shinji, et al.
Publicado: (2022)

Axitinib/pembrolizumab: Tumour-lysis-syndrome: case report
Publicado: (2020)

Pembrolizumab‐axitinib‐induced tumor lysis syndrome in a patient with metastatic renal cancer
por: Shah, Manan, et al.
Publicado: (2020)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
por: Song, Meng‐Jia, et al.
Publicado: (2021)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
por: Nishimoto, Koshiro, et al.
Publicado: (2022)

Autoimmune Myasthenia, Primary Adrenal Insufficiency, and Progressive Hypothyroidism Due to Pembrolizumab and Axitinib Combination Regimen
por: Figueroa-Perez, Nikole, et al.
Publicado: (2021)

Immune‐related dermatitis during combined treatment with pembrolizumab and axitinib in a patient with metastatic renal cell\x92carcinoma with stasis dermatitis
por: Imai, Shunsuke, et al.
Publicado: (2021)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

Reconstruction of nasal ala and tip following skin cancer resection
por: Park, Young Ji, et al.
Publicado: (2019)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
por: Zakharia, Yousef, et al.
Publicado: (2022)

High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma
por: Sang, Yun Beom, et al.
Publicado: (2022)

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
por: Suzuki, Issei, et al.
Publicado: (2021)

Exophytic growth on nasal ala
por: Casale, Fiore, et al.
Publicado: (2021)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
por: Boutros, Andrea, et al.
Publicado: (2022)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
por: Kawasoe, Chihiro, et al.
Publicado: (2023)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Selenium substituted axitinib reduces axitinib side effects and maintains its anti-renal tumor activity
por: Fu, Ying, et al.
Publicado: (2022)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

Nasal Ala Reconstruction: Surgical Conundrum
por: Ortins-Pina, Ana, et al.
Publicado: (2017)

Functional Considerations in Reconstruction of the Nasal Ala
por: Saleem, Matthew I., et al.
Publicado: (2022)

Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study
por: Tamada, Satoshi, et al.
Publicado: (2021)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_llmuali3sv5qrjo9i3saoa4au3